Vivoryon Therapeutics NV (VVY) NPV

Vivoryon Therapeutics NV is a Germany-based biopharmaceutical company focused on discovering, developing, and potentially commercializing small molecule-based medicines that modulate the activity and stability of pathologically altered proteins. The Company has established a pipeline of orally available small molecule inhibitors for various indications, focused on oral small molecule-based therapeutics with a differentiated mode of action for treating diseases with inflammatory and/or fibrotic components, such as chronic diseases of the kidney or liver. It focuses on chronic kidney disease (CKD), and more precisely- are initially targeting stage 3b and worse diabetic kidney disease (DKD). In addition to developing small molecule-based medicines, the Company is also pursuing antibody-based approaches for Alzheimer’s disease (AD).